Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency
Clinical and Translational Science · 2024-12 · 17 (12)
DOI: 10.1111/cts.70110 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 13.12.2024. Verfasst von Yu-Wei Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Polymyxin B, Renal Insufficiency. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: TTY BioPharma Company, Taiwan.
Abstract (Originalsprache)
Polymyxin B is a viable option for treating antibiotic‐resistant infections; however, current data on its pharmacokinetics, particularly in patients with renal insufficiency, remain inconclusive and necessitates further investigation. To address this gap, we conducted an open‐label, single‐center, single‐dose, parallel‐group pharmacokinetic study. Participants received an intravenous dose of 0.75 mg/kg of polymyxin B and were categorized based on their renal function: those with normal function (creatinine clearance [CLcr] ≥ 90 mL/min), mild renal insufficiency (CLcr 60–89 mL/min), and end‐stage kidney disease patients on intermittent hemodialysis (IHD) (CLcr < 10 mL/min). The pharmacokinetic parameters assessed included the area under the curve (AUC), maximum concentration ( C max ), clearance rate (CL), volume of distribution (Vz), and half‐life ( t 1/2 ). Results indicated that subjects with mild renal insufficiency exhibited pharmacokinetic profiles similar to healthy individuals. Nevertheless, in patients undergoing long‐term IHD, we observed significant differences: the AUC was 58% higher, C max was 29% lower, CL was 42% lower, Vz was 60% larger, and t 1/2 was extended by 10 h compared to healthy controls. Secondary outcomes revealed good tolerability of polymyxin B across all groups, with no serious adverse effects related to renal function. In summary, while kidney function may have a slight impact on the pharmacokinetic of polymyxin B, it does not compromise the drug's therapeutic effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Department of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
- Division of Infectious Disease, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Division of Chest Medicine, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Department of Surgery, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan City, Taiwan.
ORCID-Profile: Ming Hsien Tsai
Förderung
- TTY BioPharma Company, Taiwan
Zitieren
APA
Fang, Y. W., Huang, C. H., Jang, T. N., Lin, S. S., Wang, J. T., Huang, Y. T., & Tsai, M. H. (2024). Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency. Clinical and Translational Science, 17(12). https://doi.org/10.1111/cts.70110
Vancouver
Fang YW, Huang CH, Jang TN, Lin SS, Wang JT, Huang YT, et al. Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency. Clinical and Translational Science. 2024;17(12). doi:10.1111/cts.70110
BibTeX
@article{Fang2024,
author = {Fang, Yu-Wei and Huang, Chien-Hsien and Jang, Tsrang-Neng and Lin, Shih-Sen and Wang, Jing-Tong and Huang, Yen-Ta and Tsai, Ming Hsien},
title = {Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency},
journal = {Clinical and Translational Science},
year = {2024},
volume = {17},
number = {12},
doi = {10.1111/cts.70110}
}
EUVIMED